• home
  • ICKSH
  • Scientific Program

Scientific Program

  • Thursday, March 31
  • Friday, April 1
  • Saturday, April 2

Thursday, March 31

[JS01] KAI-KSH Joint Session

Date & Time March 31 (Thursday), 9:00-10:30 Room 1
Chairs Kyungho Choi (Seoul National University College of Medicine, Korea)
Seok-Goo Cho (The Catholic University of Korea, Korea)
Presentations
  • Next generation CAR-T cell therapy against hematological malignancies
    Kyungho Choi (Seoul National University College of Medicine, Korea)
  • Effective conditioning regimen in adoptive T cell therapy of cancer
    Chungyong Han (National Cancer Center, Korea)
  • Tissue resident memory T cells in multiple myeloma
    Yoon Seok Choi (Ajou University School of Medicine, Korea)
  • T-cell-based immunotherapeutic strategies against EBV-positive malignancies using the novel TCR specific for LMP1 antigen
    Tai-Gyu Kim (The Catholic University of Korea, Korea)

[SS01] Scientific Session 01: Pediatric Disease

Date & Time March 31 (Thursday), 9:00-10:30 Room 2
Chairs Hye Lim Jung (Sungkyunkwan University School of Medicine, Korea)
Hyeon Jin Park (National Cancer Center, Korea)
Presentations
  • Primary immune regulatory disorder for the pediatric hematologist and oncologist
    Shanmuganathan Chandrakasan (Emory University School of Medicine, USA)
  • Clonal evolution and somatic reversion in bone marrow failure
    Akiko Shimamura (Harvard Medical School, USA)
  • Molecular landscape of pediatric AML
    Soheil Meshinchi (Fred Hutchinson Cancer Research Center, USA)

[SS02] Scientific Session 02: Lymphoma (1) - B cell / CLL

Date & Time March 31 (Thursday), 9:00-10:30 Room 3
Chairs Jae-Yong Kwak (Jeonbuk National University Medical School, Korea)
Deok Hwan Yang (Chonnam National University Medical School, Korea)
Presentations
  • Molecular classification of diffuse large B-cell lymphoma and novel treatment strategies
    Daisuke Ennishi (Okayama University Hospital, Japan)
  • Novel immunotherapeutic antibodies for B-cell NHL
    Gilles Salles (Memorial Sloan Kettering Cancer Center, USA)
  • Targeting B-cell receptor and BCL-2 in chronic lymphocytic leukemia
    Susan M. O'Brien (University of California, USA)

[ES01] Education Session 01: Platelet Disorder

Date & Time March 31 (Thursday), 9:00-10:30 Room 4
Chairs Hyun Kyung Kim (Seoul National University College of Medicine, Korea)
Sung Hwa Bae (Daegu Catholic University Hospital, Korea)
Presentations
  • Diagnostic work up of inherited platelet disorder
    Bohyun Kim (Soonchunhyang University College of Medicine, Korea)
  • Recent advances in treatments of immune thrombocytopenia
    Dae Sik Kim (Korea University Guro Hospital, Korea)
  • Thrombocytopenia in pregnancy
    Young Hoon Park (Ewha Womans University Mokdong Hospital, Korea)

[PL01] Plenary Lecture 01

Date & Time March 31 (Thursday), 10:30-11:15 Room 1
Chair Dong-Wook Kim (Uijeongbu Eulji Medical Center, Eulji University, Korea)
Presentation
  • Immune landscape of hematological malignancies and functional screening tools
    Satu Mustjoki (University of Helsinki, Finland)

[SY01] Satellite Symposium 01 (Sponsored by Handok)

Date & Time March 31 (Thursday), 11:30-12:10 Room 1
Chair Jun Ho Jang (Sungkyunkwan University School of Medicine, Korea)
Presentation
  • What is the role of C5 inhibitors in PNH?
    Jin Seok Kim (Yonsei University College of Medicine, Korea)

[SY02] Satellite Symposium 02 (Sponsored by Astellas)

Date & Time March 31 (Thursday), 11:30-12:10 Room 2
Chair Hyeoung-Joon Kim (Hwasun Chonnam National University Hospital, Korea)
Presentation
  • Gilteritinib: ADMIRAL study and real world experience
    Byung Sik Cho (College of Medicine, The Catholic University of Korea, Korea)

[SY03] Satellite Symposium 03 (Sponsored by Novartis)

Date & Time March 31 (Thursday), 11:30-12:10 Room 3
Chair Sung-Soo Yoon (Seoul National University College of Medicine, Korea)
Presentation
  • Role of CD19-directed CAR-T therapy in patients with DLBCL (Novartis Kymriah Symposium)
    Koji Izutsu (National Cancer Center Hospital, Japan)

[SY04] Satellite Symposium 04 (Sponsored by Janssen)

Date & Time March 31 (Thursday), 11:30-12:10 Room 4
Chair Chang-Ki Min (Seoul St. Mary's Hospital, The Catholic University of Korea, Korea)
Presentation
  • Immunotherapy in multiple myeloma
    Ajai Chari (Mount Sinai, USA)

[YI] Young Investigator Presentation

Date & Time March 31 (Thursday), 12:40-13:40 Room 1
Chairs Je-Hwan Lee (University of Ulsan College of Medicine, Korea)
Deok Hwan Yang (Chonnam National University Medical School, Korea)
Presentations
  • Establishment of a preclinical model for acquired resistance to FMS-like tyrosine kinase 3 (FLT3) inhibitors and development of a basis for overcoming the resistance in FLT3 mutated acute myeloid leukemia
    Eun-Ji Choi (University of Ulsan College of Medicine, Korea)
  • Identification of tyrosine kinase resistance mechanisms through next-generation sequencing analysis in chronic myeloid leukemia patients
    Saeam Shin (Yonsei University College of Medicine, Korea)
  • Correlation between cytomorphological fi ndings and molecular genetic characteristics using digital imaging in patients with pre-myelodysplastic syndrome
    Chang-Hun Park (Samsung Changwon Hospital, Korea)
  • Clinical implication of plasma-derived circulating tumor DNA (ctDNA) changes in patients with advanced diff use large B-cell lymphoma treated with immunochemotherapy
    Ga-Young Song (Chonnam National University Medical School, Korea)
  • A cohort study to investigate the correlation between the microbiome and Diff use large B cell lymphoma (DLBCL)
    Sang Eun Yoon (Sungkyunkwan University School of Medicine, Korea)
  • Analysis of marrow-infi ltrating T cell subpopulation in newly diagnosed multiple myeloma
    Myung-Won Lee (Chungnam National University College of Medicine, Korea)
  • Multi-omics analysis of pediatric patients undergoing haploidentical hematopoietic stem cell transplantation with busulfun-based conditioning regimen and post-transplant cyclophosphamide
    Kyung Taek Hong (Seoul National University College of Medicine, Korea)
  • Development of acute GVHD biomarkers in pediatric patients
    Sung Han Kang (Asan Medical Center, Korea)

[OP01] Oral Presentation 01: AML, MDS

Date & Time March 31 (Thursday), 12:40-13:40 Room 2
Chairs Byung-Soo Kim (Korea University College of Medicine, Korea)
Dong-Yeop Shin (Seoul National University College of Medicine, Korea)
Presentations
  • Potential prognostic signifi cance of promoter methylation status of DNA repair genes at diagnosis in acute myeloid leukemia: analysis of TCGA-LAML cohort and patients in a single institution
    Sholhui Park (Ewha Womans University School of Medicine, Korea)
  • TP53-mutated AML with high variant allele frequency show better survival outcome with hypomethylating agents than with cytarabine-based induction
    Hye Won Kook (Yonsei University College of Medicine, Korea)
  • WT1 gene expression in primary acute myeloid leukemia
    Ishan Gupta (All India Institute of Medical Sciences, India)
  • Preliminary results by age group of treatment with CPX-351 plus venetoclax in adults with newly diagnosed AML: subgroup analysis of the v-fast trial
    Vinod Pullarkat (City of Hope Comprehensive Cancer Center, USA)
  • A randomized, phase II, comparative study with a parallel control for evaluating the efficacy and safety of 5-day azacitidine for patients with lower-risk MDS
    Silvia Park (The Catholic University of Korea, Korea)

[OP02] Oral Presentation 02: Lymphoma, Histiocytosis

Date & Time March 31 (Thursday), 12:40-13:40 Room 3
Chairs Ki-Seong Eom (College of Medicine, The Catholic University of Korea, Korea)
Sukjoong Oh (Hanyang University Seoul Hospital, Korea)
Presentations
  • High incidence of MYD88 mutation associated with mutated IGHV gene in Korean chronic lymphocytic leukemias
    Ari Ahn (The Catholic University of Korea, Korea)
  • First interim analysis results of ALPINE phase 3 study of zanubrutinib vs ibrutinib in R/R chronic lymphocytic leukemias/ small lymphocytic leukemias
    Won Seog Kim (Sungkyunkwan University School of Medicine, Korea)
  • CD 19 chimeric antigen receptor T cell therapy for relapsed/refractory B-cell lymphoid malignancies: the effi cacies and safeties of tisa-cel in the real world
    Sang Eun Yoon (Sungkyunkwan University School of Medicine, Korea)
  • Long-term real-world experience of Castleman’s disease treatment
    Gi June Min (The Catholic University of Korea, Korea)
  • Clinical analysis 0f modifi ed HLH-04 regimen for the treatment of childhood hemophagocytic lymphohistiocytosis
    Fenfen Cheng (Capital Medical University, China)

[OP03] Oral Presentation 03: Laboratory Hematology

Date & Time March 31 (Thursday), 12:40-13:40 Room 4
Chairs Myung-Hyun Nam (Korea University Anam Hospital, Korea)
Young-Uk Cho (University of Ulsan College of Medicine, Korea)
Presentations
  • Clinical-biochemical screening and genetic analysis of suspected inherited iron meNGStabolism related anaemias using targeted ngs approach
    Pankaj Sharma (PGIMER, India)
  • Comparison of clinical features, genetic alterations, and outcomes in patients with prefibrotic, overt primary myelofibrosis, and secondary myelofibrosis
    Tong Yoon Kim (The Catholic University of Korea, Korea)
  • Flow cytometry of body fluid specimens: diagnostic value in hematologic malignancy
    Smeeta G (All India Institute of Medical Sciences, India)
  • Single-cell analysis of Multiple Myelomas refines bortezomib treatment responsiveness
    Sung-Soo Park (The Catholic University of Korea, Korea)
  • Empagliflozin modulates CD4+ T cell differentiation via metabolic reprogramming in immune thrombocytopenia
    Qin Jing (Shandong University, China)

[AS01] Asian Session I: AA

Date & Time March 31 (Thursday), 13:55-14:55 Room 1
Chairs Jong Wook Lee (Seoul St. Mary's Hospital, The Catholic University of Korea, Korea)
Hoon Kook (Chonnam National University Medical School, Korea)
Presentations
  • Korean treatment guideline for aplastic anemia
    Jun Ho Jang (Sungkyunkwan University School of Medicine, Korea)
  • Aplastic anemia immunosuppressive therapy in China
    Zhao Xin (Institute of Hematology and Blood Diseases Hospital, China)
  • Clinical significance of detecting HLA-class I allele-lacking leukocytes in patients with aplastic anemia
    Kohei Hosokawa (Kanazawa University, Japan)

[SS03] Scientific Session 03: MPN

Date & Time March 31  (Thursday), 13:55-15:25 Room 2
Chairs Chul Won Choi (Korea University Guro Hospital, Korea)
Sung-Yong Kim (Konkuk University School of Medicinek, Korea)
Presentations
  • Recent advances in molecular diagnosis, prognosis and monitoring of MPNs
    Myungshin Kim (The Catholic University of Korea, Korea)
  • Molecular mechanisms underlying the development of MPN by mutant calreticulin and the therapeutic potential of an antibody targeting mutant calreticulin
    Norio Komatsu (Juntendo University Graduate School of Medicine, Japan)
  • Targeting pro-inflammatory signaling, including IL8, in myelofibrosis: the pathway into the clinic
    Andrew J. Dunbar (Memorial Sloan Kettering Cancer Center, USA)

[SS04] Scientific Session 04: MM

Date & Time March 31 (Thursday), 13:55-15:25 Room 3
Chairs Dong Soon Lee (Seoul National University College of Medicine, Korea)
Kihyun Kim (Sungkyunkwan University School of Medicine, Korea)
Presentations
  • Evolution of myeloma from the normal plasma cell to disease complexity
    Niccolo Bolli  (University of Milan, Italy)
  • The power of ONE: immunology in the age of single cell genomics
    Ido Amit  (Weizmann Institute, Israel)
  • Clinical implication of immune network in multiple myeloma
    Je-Jung Lee, (Chonnam National University Medical School, Korea)

[ES02] Education Session 02: AML

Date & Time March 31 (Thursday), 13:55-15:25 Room 4
Chairs Byung Sik Cho (College of Medicine, The Catholic University of Korea, Korea)
Dong-Yeop Shin (Seoul National University College of Medicine, Korea)
Presentations
  • Human AML stem cell: evolution of concept
    Dong-Yeop Shin (Seoul National University Hospital, Korea)
  • Recent update of AML risk stratification
    Hyoeun Shim (National Cancer Center, Korea)
  • FLT3 mutated AML
    Jae-Sook Ahn (Chonnam National University Medical School, Korea)

[JS02] KOGO-KSH Joint Session

Date & Time March 31 (Thursday), 15:40~17:10 Room 1
Chairs Hae-Ock Lee (The Catholic University of Korea, Korea)
Sun-Young Kong (National Cancer Center, Korea)
Presentations
  • Developing single-cell data integration pipeline to find novel cell types and gene markers for immune diseases
    Jong-Eun Park (Korea Advanced Institute of Science and Technology, Korea)
  • Detection of enhancer hijacking of oncogenes in multiple myeloma
    Jin-Wu Nam (Hanyang University, Korea)
  • Pharmacogenetics of childhood acute lymphoblastic leukemia
    Hyery Kim (University of Ulsan College of Medicine, Korea)
  • Evaluating leukemic structural variations using optical genome mapping
    Saeam Shin (Yonsei University College of Medicine, Korea)

[SS05] Scientific Session 05: CML

Date & Time March 31 (Thursday), 15:40~17:10 Room 2
Chairs Chul Won Jung (Sungkyunkwan University School of Medicine, Korea)
Won Sik Lee (Inje University College of Medicine, Korea)
Presentations
  • Resistance mechanism in CML
    Kimmo Porkka (Helsinki University Central Hospital, Finland)
  • Mutational landscape in CML
    Simona Soverini (University of Bologna, Italy)
  • CML/MPN stem cells and the bone marrow microenvironment
    Steffen Koschmieder (RWTH Aachen University, Germany)

[SS06] Scientific Session 06: Cell Therapy / Transplantation

Date & Time March 31 (Thursday), 15:40~17:10 Room 3
Chairs Hyeon-Seok Eom (National Cancer Center, Korea)
Hyoung Jin Kang (Seoul National University College of Medicine, Korea)
Presentations
  • Immune landscapes and chemotherapy resistance in AML
    Sergio Rutella (Nottingham Trent University, UK)
  • Towards next-generation T cell engineering for cancer
    Chan Hyuk Kim (Korea Advanced Institute of Science and Technology, Korea)
  • Endogenous retroviruses as a source of tumor antigens in solid tumors and acute myeloid leukemia
    Stéphane Depil (Université Claude Bernard Lyon 1, France)

[ES03] Education Session 03: Thrombosis/ Hemostasis

Date & Time March 31 (Thursday), 15:40~17:10 Room 4
Chairs Sung-Hyun Kim (Dong-A University College of Medicine, Korea)
Jin-Yeong Han (Dong-A University College of Medicine, Korea)
Presentations
  • Advances in laboratory assessment in thrombosis/hemostasis
    Jaewoo Song (Yonsei University College of Medicine, Korea)
  • Cancer-associated thrombosis
    Ho-Young Yhim (Jeonbuk National University Medical School, Korea)
  • Recent advances in the management of immune mediated TTP
    Sung Hwa Bae (Daegu Catholic University Hospital, Korea)

Friday, April 1

[JS03] ASH-KSH Joint Symposium: Histiocytosis

Date & Time April 1 (Friday), 9:00-10:30 Room 1
Chairs Jane Winter (Feinberg School of Medicine, USA)
Ho Joon Im (University of Ulsan College of Medicine, Korea)
Presentations
  • Biologic and clinical consequences of the BRAFV600E mutation in langerhans cell histiocytosis
    Kenneth McClain (Texas Children's Cancer Center, USA)
  • Advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis
    Kim E. Nichols (St. Jude Children's Research Hospital, USA)
  • Current status of diagnosis and treatment of Langerhans cell histiocytosis in Korea
    Kyung-Nam Koh (University of Ulsan College of Medicine, Korea)
  • Adult hemophagocytic lymphohistiocytosis in Korea
    Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea)

[SS07] Scientific Session 07: Stem Cell Biology

Date & Time April 1 (Friday), 9:00-10:30 Room 2
Chairs Myung Geun Shin (Chonnam National University Medical School, Korea)
June-Won Cheong (Yonsei University College of Medicine, Korea)
Presentations
  • Losing sense of self and surroundings: hematopoietic stem cell aging and leukemic transformation
    Emmanuelle Passegue (Columbia University Irving Medical Center, USA)
  • Hematopoietic stem and progenitor cell signaling in the niche
    Peter Kurre (Children's Hospital of Philadelphia, USA)
  • Thrombopoietin as an expansion factor for hematopoietic stem cells
    Toshio Suda (Kumamoto University, Japan)

[SS08] Scientific Session 08: Thrombosis & Hemostasis

Date & Time April 1 (Friday), 9:00-10:30 Room 3
Chairs Soo-Mee Bang (Seoul National University College of Medicine, Korea)
Seongsoo Jang (University of Ulsan College of Medicine, Korea)
Presentations
  • Mechanism of thrombosis and bleeding in viral infection: focusing on COVID-19
    Marcel Levi (University College London Hospitals NHS Foundation Trust, UK)
  • COVID-19 vaccine related hematologic manifestations
    Soo-Mee Bang (Seoul National University Bundang Hospital, Seoul National University College of Medicine, Korea)
  • Thrombotic thrombocytopenic purpura in 2022 - novel therapies and focus on long term outcomes
    Shruti Chaturvedi (Johns Hopkins University School of Medicine, USA)

[ES04] Education Session 04: Plasma Cell Disorder

Date & Time April 1 (Friday), 9:00-10:30 Room 4
Chairs Je-Jung Lee (Chonnam National University Medical School, Korea)
Dok Hyun Yoon (Asan Medical Center, University of Ulsan College of Medicine, Korea)
Presentations
  • Diagnosis and management of monoclonal gammopathy of clinical significance
    Hyungwoo Cho (University of Ulsan College of Medicine , Korea)
  • Update in the POEMS syndrome
    Yu Ri Kim (Yonsei University College of Medicine, Korea)
  • Update in the primary plasma cell leukemia
    Sung-Hoon Jung (Chonnam National University Hwasun Hospital, Korea)

[PL02] Plenary Lecture 02

Date & Time April 1 (Friday), 10:30-11:15 Room 1
Chair Sung-Soo Yoon (Seoul National University College of Medicine, Korea)
Presentation
  • Rational development of targeted therapies to cure molecular subtypes of DLBCL
    Louis M. Staudt (National Cancer Institute, USA)

[SY05] Satellite Symposium 05 (Sponsored by Kyowa Kirin)

Date & Time April 1 (Friday), 11:30-12:10 Room 1
Chair Jong Wook Lee (Seoul St. Mary's Hospital, The Catholic University of Korea, Korea)
Presentation
  • Role of romiplostim in ITP and AA
    Jun Ho Jang (Sungkyunkwan University School of Medicine, Korea)

[SY06] Satellite Symposium 06 (Sponsored by Otsuka)

Date & Time April 1 (Friday), 11:30-12:10 Room 2
Chair Dong-Wook Kim (Uijeongbu Eulji Medical Center, Eulji University, Korea)
Presentation
  • The updated information of ponatinib use in chronic myeloid leukemia
    Jorge E. Cortes (Georgia Cancer Center, USA)

[SY07] Satellite Symposium 07 (Sponsored by Roche)

Date & Time April 1 (Friday), 11:30-12:10 Room 3
Chair Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea)
Presentation
  • Strategic treatment for diffuse large B-Cell lymphoma; incorporating polatuzumab to DLBCL
    Christopher Flowers (The University of Texas MD Anderson Cancer Center, USA)

[SY08] Satellite Symposium 08 (Sponsored by BMS-Celgene)

Date & Time April 1 (Friday), 11:30-12:10 Room 4
Chair Kihyun Kim (Sungkyunkwan University School of Medicine, Korea)
Presentation
  • Optimal treatment with IMiDs in newly diagnosed multiple myeloma
    Luciano J. Costa (The University of Alabama at Birmingham, USA)

[OP04] Oral Presentation 04: ALL

Date & Time April 1 (Friday), 12:40-13:40 Room 1
Chairs Inho Kim (Seoul National University Hospital, Korea)
Kyung-Nam Koh (University of Ulsan College of Medicine, Korea)
Presentations
  • Expression pattern of non-homologous end joining DNA repair pathway genes and its clinical relevance in T-lineage acute lymphoblastic leukemia
    Anita Chopra (All India Institute of Medical Sciences, India)
  • Interim analysis of the prospective phase II study of individualized 6-mercaptopurine dosing based on pharmacogenomics in childhood acute lymphoblastic leukemia
    Hyery Kim (University of Ulsan College of Medicine, Korea)
  • Current treatment trends of infant Leukemia in Korea based on a retrospective multicenter reivew: the Korean society of hematology, pediatric all working group
    Seung Min Hahn (Yonsei Cancer Center, Korea)
  • Prognostic impact of cytogenetic classifi cation in adult all patients treated with intensive chemotherapy and allogeneic HCT-based post-remission therapy
    Jae-Ho Yoon (The Catholic University of Korea, Korea)
  • Defi france registry study: effi cacy and safety of defi brotide for the treatment of severe/very severe vod/sos after hematopoietic cell transplantation
    Mohamad Mohty (Hôpital St Antoine, Sorbonne University, France)

[OP05] Oral Presentation 05: Anemia, BMF, CML, MPN

Date & Time April 1 (Friday), 12:40-13:40 Room 2
Chairs Hawk Kim (Gachon University College of Medicine, Korea)
Sung-Eun Lee (The Catholic University of Korea, Korea)
Presentations
  • Causal role of iron status on anemia and on cardiometabolic outcomes among UK whites and Taiwanese Han Chinese using hemoglobin-genetic risk scores
    Vanessa Joy Timoteo (National Yang Ming Chiao Tung University and Academia Sinica, Taiwan)
  • Favorable outcomes of familial-mismatched donor transplantation using post-transplant cylophosphamide(PTCy) for pediatric severe aplastic anemia
    Jae Won Yoo (The Catholic University of Korea, Korea)
  • The long-term effi cacy and safety of eculizumab in patients with paroxysmal nocturnal hemoglobinuria; retrospective study on behalf of Korean society of hematology aplastic anemia working party
    Jin Seok Kim (Yonsei University College of Medicine, Korea)
  • Response to chemotherapy in patients with juvenile Myelomonocytic Leukemia in Korea: The Korean pediatric hematology-oncology group(KPHOG)
    Eun Sang Yi (Korea University College of Medicine, Korea)
  • A multicenter, open-label, phase IV clinical study for effi cacy and safety evaluation of anagrelide in patients with treatment-naïve, high-risk essential thrombocythemia as a primary treatment
    Ja Min Byun (Seoul National University Hospital, Korea)

[OP06] Oral Presentation 06: MM

Date & Time April 1 (Friday), 12:40-13:40 Room 3
Chairs Jeong Yeal Ahn (Gachon University Gil Medical Center, Korea)
Min Kyoung Kim (Yeungnam University Medical Center, Korea)
Presentations
  • Prognostic role of the ratio of natural killer to regulatory T cells in multiple myeloma treating lenalidomide and dexamethasone
    Seung Yeon Kim (The Catholic University of Korea, Korea)
  • Rejuvenation of antigen-specific CD8+ T cells using induced pluripotent stem cell technology and specific regulatory pathways for T cell commitment
    Jooeun Bae (Harvard Medical School, USA)
  • Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in multiple myeloma: KMMWP-1801 study
    Ga-Young Song (Chonnam National University Medical School, Korea)
  • Comparative analysis of single versus tandem autologous stem cell transplantation in patients with multiple myeloma in Korea: the KMM2102 study
    Jongheon Jung (National Cancer Center, Korea)
  • Subcutaneous daratumumab with bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed light chain (AL) amyloidosis: 18-month analysis of the phase 3 andromeda study
    Kihyun Kim (Sungkyunkwan University School of Medicine, Korea)

[OP07] Oral Presentation 07: Platelet, Transfusion

Date & Time April 1 (Friday), 12:40-13:40 Room 4
Chairs Eun Sun Yoo (Ewha Womans University Seoul Hospital, Korea)
Jaewoo Song (Yonsei University College of Medicine, Korea)
Presentations
  • 2021 operation of the surveillance system of covid-19 vaccination induced thrombosis with thrombocytopenia syndrome in Korea
    Daehyun Chu (University of Ulsan College of Medicine, Korea)
  • Validation of khorana score in cancer patients undergoing chemotherapy with east asian ethnicity
    Junshik Hong (Seoul National Universityi College of Medicine, Korea)
  • Acute transfusion reactions of pediatric blood transfusions at Chiang Mai university hospital
    Pattira Rungruansarn (Chiang Mai University, Thailand)
  • Risk factors of platelet transfusion refractoriness in patients with AA/MDS who receive allogeneic hematopoietic stem cell transplantation
    Jaeik Oh (Seoul National University Hospital, Korea)
  • Combining pharmacokinetics and comprehensive evaluation system to individualize the prophylaxis in pediatric patients with hemophilia A
    Kun Huang (Capital Medical University, China)

[PS01] Presidential Lecture

Date & Time April 2 (Friday), 13:55-14:40 Room 1
Chair Je-Hwan Lee (University of Ulsan College of Medicine, Korea)
Presentation
  • Toward precision medicine in AML
    Hartmut Döhner (University of Ulm, Germany)

[MS01] MOU Country Session 01

Date & Time April 1 (Friday), 14:40-15:40 Room 1
Chairs Jae Hoon Lee (Gachon University Gil Medical Center, Korea)
Jin Seok Kim (Yonsei University College of Medicine, Korea)
Presentations
  • Managing multiple myeloma in a resource-limited region: diagnosis and treatment in Armenia
    Yervand K. Hakobyan (Armenian Hematology Association, Armenia)
  • Renal involvement in plasma cell disorder: learning from real-life practice
    Suporn Chuncharunee (Ramathibodi hospital, Thailand)
  • Treatment sequence decision in multiple myeloma considering reimbursement status
    Youngil Koh (Seoul National University Hospital, Korea)

[SS09] Scientific Session 09: MDS

Date & Time April 1 (Friday), 14:40-16:10 Room 2
Chairs Yoo-Jin Kim (College of Medicine, The Catholic University of Korea, Korea)
Yoon Hwan Chang (Seoul National University Hospital, Korea)
Presentations
  • Pathophysiology of spliceosome mutations in MDS
    Andrea Pellagatti (University of Oxford, UK)
  • Role of extracellular vesicles and miRNA in myelodysplastic syndromes
    Sophie Park (CHU de Grenoble Service hematologie clinique, France)
  • Challenges in the diagnosis and treatment of overlap MDS/MPN syndromes
    Antonio Almeida (Hospital da Luz Lisboa, Portugal)

[SS10] Scientific Session 10: ALL

Date & Time April 1 (Friday), 14:40-16:10 Room 3
Chairs Nack-Gyun Chung (The Catholic University of Korea, Korea)
Ho-Jin Shin (Pusan National University School of Medicine, Korea)
Presentations
  • Chemotherapy vs. allogeneic HSCT for Ph–negative adult ALL
    Josep-Maria Ribera (ICO-Hospital Germans Trias i Pujol, Spain)
  • Clonal heterogeneity in ALL
    Jan Cools (Center for Human Genetics, Belgium)
  • Adoptive cellular immunotherapies based on chimeric antigen receptors
    Pablo Menendez (Josep Carreras Leukemia Research Institute, Spain)

[ES05] Education Session 05: AA and BMF

Date & Time April 1 (Friday), 14:40-16:10 Room 4
Chairs Myungshin Kim (The Catholic University of Korea, Korea)
Yeung-Chul Mun (Ewha Womans University College of Medicine, Korea)
Presentations
  • Genetics and genomics of bone marrow failure syndrome
    Hyun-Young Kim (Sungkyunkwan University School of Medicine, Korea)
  • Aplastic anemia: transplant vs non-transplant options
    Ik-Chan Song (Chungnam National University Hospital, Korea)
  • Overview of bone marrow failure syndrome
    Meerim Park (National Cancer Center, Korea)

[JS04] EHA-KSH Joint Symposium: CML

Date & Time April 1 (Friday), 16:25-17:55 Room 1
Chairs Kirsten Grønbæk (University of Copenhagen, Denmark)
Sang Kyun Sohn (Kyungpook National University School of Medicine, Korea)
Presentations
  • Failing a second-generation TKI: when the guidelines don’t always help
    Jane Apperley (Imperial College London, UK)
  • Discontinuation of tyrosine kinase inhibitors in CML patients in clinical practice
    Antonio Almeida (Hospital da Luz Lisboa, Portugal)
  • Second and later line therapy : the role of ponatinib in Korean patients with CML
    Jeong-Ok Lee (Seoul National University Bundang Hospital, Korea)
  • Stopping tyrosine kinase inhibitor in CML; perspectives from Korean data
    Hawk Kim (Gachon University College of Medicine, Korea)

[SS11] Scientific Session 11: Adv Technology

Date & Time April 1 (Friday), 16:25-17:55 Room 2
Chairs Duck Cho (Sungkyunkwan University School of Medicine, Korea)
Ji-Myung Kim (Chungnam National University Hospitalm, Korea)
Presentations
  • Hematopoiesis and leukemia through the lens of single cell genomics
    Lars Velten (Centre for Genomic Regulation, Spain)
  • Computer vision in hematologic malignancies
    Oscar Brück (University of Helsinki, Finland)
  • Hydrogel-based stamping technology for solution-free blood cell staining
    Dongyoung Lee (Noul Co., Ltd, Korea)

[SS12] Scientific Session 12: Benign Hematology

Date & Time April 1 (Friday), 16:25-17:55 Room 3
Chairs Deog-Yeon Jo (Chungnam National University College of Medicine, Korea)
Hyoung Soo Choi (Seoul National University College of Medicine, Korea)
Presentations
  • The iron-erythropoiesis cross-talk in health and disease
    Antonella Nai (San Raffaele Scientific Institute, Italy)
  • Autoimmune hemolytic anemia : state-of-the-art hypotheses on pathogenesis and their application to treatment
    Bruno Fattizzo (Università degli Studi di Milano, Italy)
  • Cold agglutinin disease: an update on pathogenesis and future prospects on therapy
    Sigbjørn Berentsen (Haugesund Hospital, Norway)

[ES06] Education Session 06: Lymphoma

Date & Time April 1 (Friday), 16:25-17:55 Room 4
Chairs Jong Ho Won (Soonchunhyang University College of Medicine, Korea)
Young Rok Do (Keimyung University School of Medicine, Korea)
Presentations
  • Lymphoma pathology: basic immunohistochemistry for lymphoma diagnosis
    Junhun Cho (Sungkyunkwan University School of Medicine, Korea)
  • Staging and response assessment of lymphoma
    Kwai Han Yoo (Gachon University Gil Medical Center, Korea)
  • Treatment of indolent lymphoma
    Seong Hyun Jeong (Ajou University School of Medicine, Korea)

Saturday, April 2

[AS02] Asian Session II: Pediatric ALL

Date & Time April 2 (Saturday), 09:00-10:00 Room 1
Chairs Chuhl Joo Lyu (Yonsei University Health System, Korea)
Keon Hee Yoo (Sungkyunkwan University School of Medicine, Samsung Medical Center, Korea)
Presentations
  • Ma-Spore ALL studies: truly Asia approach to curing childhood ALL
    Allen E.J. Yeoh (National University of Singapore, Singapore)
  • Childhood ALL in Thailand and multicenter studies of Thai pediatric oncology group
    Samart Pakakasama (Mahidol University, Thailand)
  • The adherence to MRD time points improves treatment outcomes of childhood ALL in Taiwan: the experience of TPOG-ALL-2013 protocol
    Hsi-Che Liu (Mackay Memorial Hospital, Taiwan)

[SS13] Scientific Session 13: AML

Date & Time April 2 (Saturday), 09:00-10:30 Room 2
Chairs Hee-Je Kim (The Catholic University of Korea, Korea)
Young Kyung Lee (Hallym University College of Medicine, Korea)
Presentations
  • AML microenvironment and FLT3 inhibitor resistance
    Elie Traer (Oregon Health & Science University, USA)
  • Targeting TP53 mutation in AML
    David A. Sallman (H. Lee Moffitt Cancer Center and Research Institute, USA)
  • Adaptive immune resistance and immune evasion by programmed death-1 homolog (PD-1H/VISTA) in AML
    Tae Kon Kim (Vanderbilt University Medical Center, USA)

[SS14] Scientific Session 14: Lymphoma (2) - T cell / HL

Date & Time April 2 (Saturday), 09:00-10:30 Room 3
Chairs Won Seog Kim (Sungkyunkwan University School of Medicine, Korea)
Ho-Young Yhim (Jeonbuk National University Hospital, Korea)
Presentations
  • Genomic landscape of peripheral T-cell lymphomas
    Keisuke Kataoka (National Cancer Center Research Institute, Japan)
  • T-cell lymphomas of follicular helper T-cell derivation: pathology, mechanisms and therapeutic implications
    Laurence de Level (Lausanne University Hospital, Switzerland)
  • Targeted therapy to small molecules in peripheral T cell lymphomas
    Deok Hwan Yang (Chonnam National University Medical School, Korea)

[ES07] Education Session 07: Supportive Care

Date & Time April 2 (Saturday), 09:00-10:30 Room 4
Chairs Seong Kyu Park (Soonchunhyang University Bucheon Hospital, Korea)
Hyo Jung Kim (Hallym University College of Medicine, Korea)
Presentations
  • Comprehensive geriatric assessment in older patients for intensive chemotherapy
    Jung-Yeon Choi (Seoul National University Bundang Hospital, Korea)
  • Evaluation and management of platelet transfusion refractoriness
    Dae-Hyun Ko (University of Ulsan College of Medicine, Korea)
  • Advances in management of invasive fungal infections: perspectives on hematologic diseases
    Dong-Gun Lee (Seoul St. Mary's Hospital, The Catholic University of Korea, Korea)

[PL03] Plenary Lecture 03

Date & Time April 2 (Saturday), 10:30-11:15 Room 1
Chair Chuhl Joo Lyu (Yonsei University Health System, Korea)
Presentation
  • Improving outcomes after CD19-targeted CAR T-cell therapy
    Jordan Gauthier (University of Washington, USA)
Organized by
Supported by

Sponsored by